On November 4, 2015, CytoSorbents Corporation (the Company) entered into a Controlled Equity Offering
Sales Agreement (the Sales Agreement) with Cantor Fitzgerald & Co., as agent (Cantor), pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Companys common stock, par value $0.001 per share (the Common Stock), having an aggregate offering price of up to $25,000,000 (the Shares). Any Shares offered and sold will be issued pursuant to the Companys shelf registration statement on Form S-3 (Registration No. 333-205806) and the related prospectus previously declared effective by the Securities and Exchange Commission (the SEC) on July 29, 2015 (the Registration Statement), as supplemented by a prospectus supplement, dated No vember 4, 2015, which the Company will file with the SEC pursuant to Rule 424(b)(5) under the Securities Act.
Under the Sales Agreement, Cantor may sell Shares by any method permitted by law and deemed to be an at the market offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Capital Market, on any other existing trading market for the Common Stock or to or through a market maker. In addition, under the Sales Agreement, Cantor may sell the Shares by any other method permitted by law, including in privately negotiated transactions. The Company may instruct Cantor not to...